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Unexplained thrombosis of the aortic arch with distal
embolization in a patient with altered fibrin clot properties 
Tomasz Ciurus1, Anetta Undas2, Malgorzata Lelonek1
The pathophysiology of arterial thrombosis in young patients remains
unclear. Traditional cardiovascular risk factors explain not more than 50%
of cases of arterial thrombosis [1]. It is known that arterial inflammation,
autoimmune diseases, endothelial dysfunction, atherosclerosis, blood flow
abnormalities, and finally, altered platelet function, coagulation or fibri-
nolysis predispose to arterial thrombosis. The common thrombophilic fac-
tors, factor V Leiden and prothrombin G20210A polymorphism, are incon-
sistently associated with arterial thrombosis [2]. Growing evidence indicates
that the structure of a fibrin clot composed of compact thin fibrin net-
works can predispose to arterial thrombosis [3]. However, a role of abnor-
mal fibrin clot characteristics in arterial thrombosis different from coro-
nary artery thrombosis is unknown. Aortic arch thrombosis (AAT) is a rare
pathology and generally is associated with diffuse atherosclerosis of the
aortic arch in elderly patients, aortic aneurysm or dissections [4]. Howev-
er, mobile thrombi in the aortic arch have also been reported in younger
patients [5]. 
We report here a young man who developed unexplained AAT and sub-
sequent emboli to the lower limbs and, importantly, we detected novel
prothrombotic fibrin alterations that may be behind this thrombosis.
A 35-year-old man, with no medical history (normal arterial, diabetes
mellitus, lipid disorders, no smoking, normal weight) was admitted to the
hospital due to paresis of the lower extremities. The patient was para-
plegic; femoral and distal pulses were nonpalpable. Computed angiogra-
phy showed an intraaortic mass which straddled the aortic bifurcation and
extended to just below the renal arteries, indicative of a thrombus. Urgent
embolectomy and fasciotomy in both lower extremities were performed.
An electrocardiogram showed a regular sinus rhythm at 70 beats/min,
with no history of atrial fibrillation. Routine laboratory investigations did
not show any abnormalities, with a normal value of blood lipids. C-reac-
tive protein level was 2.82 mg/l and fibrinogen 4.11 g/l. Thrombophilia
screening, including prothrombin gene 20210A mutation, factor V Leiden,
lupus anticoagulant, antiphospholipid antibodies, protein C, free protein S
and antithrombin, yielded negative results. 
Interestingly, his mother underwent embolectomy of the aortic arch
and brachiocephalic trunk, when she was 42 years.
In search for causes of arterial thrombosis one month after surgery,
transoesophageal echocardiography was performed and revealed in the
aortic arch a pedunculated mass of 2.6 cm × 1.3 cm, with no visible ath-
erosclerotic plaques. Cardiac magnetic resonance imaging (MRI) showed
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a well-demarcated mass attached to the aortic arch
wall and obstructing the brachiocephalic trunk
ostium (Figure 1 A-B). There was no amplification
of the contrast in the perfusion image of MRI, thus
indicating the thrombus (Figure 1 A). 
The patient received intravenous unfractionat-
ed heparin followed by vitamin K antagonist (VKA)
administration with a target international normal-
ized ratio of 2-3 that resulted in a slight reduction
in thrombus size within the first 3 weeks of thera-
py. At 12 months transoesophageal echocardiogra-
phy, however, did not show any pathology in the
aortic arch.
Given the data showing altered fibrin clot prop-
erties in patients with venous thromboembolism
[6] and ischemic stroke [7], we performed plasma
fibrin structure/function analysis [6], which demon-
strated markedly altered fibrin clot characteristics,
including reduced clot permeability (a marker of
pore size, Ks) and compaction (a marker of clot stiff-
ness) combined with faster clot formation (short-
er lag phase of fibrin formation) and impaired clot
lysis (prolonged lysis time and slower rate of 
D-dimer release from clots) as compared to values
obtained for anticoagulated patients with distal
deep vein thrombosis (Table I).  
Traditional cardiovascular risk factors explain
arterial thrombosis in older patients [1], especially
after interventions [8]. In young patients without
cardiac risk factors, mostly arterial thrombotic
events occurred related to atrial fibrillation or fac-
tor V Leiden. Thrombophilia screening fails to iden-
tify predisposing factors in 30% to 50% of idiopathic
thrombosis patients [3]. A new risk factor for pro-
thrombotic events revealed in venous thromboem-
bolism, altered fibrin clot properties, is rarely
described in patients with arterial thrombosis [3]. 
This study is the first to demonstrate AAT in
a man with altered clot properties and reduced sus-
ceptibility to lysis. In the search for any cause of
AAT in the patient with negative thrombophilia
screening, abnormal features of plasma fibrin clot
structure/function were detected. The propensity
to faster formation of compact fibrin clots is asso-
ciated with resistance to fibrinolysis, as evidenced
by longer lysis time and lower lysis rate (Table I).
By analogy to cryptogenic venous thrombosis [6]
or stroke [7], such properties could also explain the
Figure 1. A mass attached to the aortic arch wall (arrow in the image) and closing brachiocephalic trunk ostium in
MRI with a contrast injection (no amplification of the contrast in sequence of perfusion). A – a perfusion scan, 
B – a cine image
Ao – aorta, LV – left ventricle
A B
Table I. Comparisons of fibrin clot features
Feature Patient Controls with INR 
2-3 (n = 20) 
Ks [10–9 cm2] 6.8 8.6 ±1
Compaction [%] 49 63.8 ±6.2
Lag phase [s] 43 46.2 ±3.4
ΔAbs (405 nm) 0.89 0.72 (0.68-0.8)
t50% [min] 9.7 7 ±1
D-D max [mg/l] 3.98 3.1 (2.6-3.6)
D-D rate [mg/l/min] 0.069 0.079 (0.075-0.085)
Values are given as mean ± SD. Ks indicates permeability coefficient,
ΔAbs (405 nm) – maximum absorbance of fibrin gel at 405 nm deter-
mined by using turbidimetry, t50% – half-lysis time, D-D max – maxi-
mum D-dimer levels in lysis assay 2, D-D rate – maximum rate of
increase in D-dimer levels in lysis assay 2
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occurrence of unexplained arterial thrombosis.
Moreover, altered fibrin clot structure/function may
be associated with an unusual location of throm-
bus formation.
Mechanisms underlying the fibrin clot charac-
teristics in the current patient remain unclear and
most likely combine environmental as well as
genetic factors [3]. Although a positive familial his-
tory of AAT suggests a genetic background, we can-
not definitely rule out in our patient other factors
such as inflammatory, lipoprotein (a) (not meas-
ured in the present study) [9], or the effect of
platelets and blood cells. An influence of other as
yet unidentified genetic factors is also suggested.
It is unknown whether prolonged heparin admin-
istration, thrombolysis, high-intensity anticoagu-
lant or a surgical excision is the best therapeutic
option in such cases. Our study supports VKA ther-
apy in AAT as shown in previous reports [3]. This
approach is likely to prevent thrombus recurrence
and its embolic complications. Our patient was also
successfully treated with VKA since low thrombin
activity during stable anticoagulation facilitates clot
lysis. 
In conclusion, the current report suggests that
unfavorable fibrin clot features predispose to unex-
plained arterial thrombosis and embolism in young
patients without thrombophilic factors, thus repre-
senting potential novel risk factors for thrombosis
at untypical locations.
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